REGULATION OF THE RESPONSE TO BACTERIAL LIPOPOLYSACCHARIDE BY ENDOGENOUS AND EXOGENOUS LIPOPOLYSACCHARIDE-BINDING PROTEINS

被引：6

作者：

MARRA, MN

THORNTON, MB

SNABLE, JL

LEONG, S

LANE, J

WILDE, CG

SCOTT, RW

机构：

[1] Incyte Pharmaceuticals, Palo Alto, CA

[2] Genentech Inc., South San Francisco, CA

来源：

BLOOD PURIFICATION | 1993年 / 11卷 / 02期

关键词：

LIPOPOLYSACCHARIDE; BACTERICIDAL PERMEABILITY-INCREASING PROTEIN; LIPOPOLYSACCHARIDE BINDING PROTEIN; HA-1A; XMMEN-OE5;

D O I：

10.1159/000170107

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Bactericidal/permeability-increasing protein (BPI) is a natural constituent of human neutrophils. Recombinant BPI has been shown to bind to bacterial lipopolysaccharide (LPS), and to neutralize the ability of LPS to stimulate inflammatory cells in vitro and in vivo. BPI shares sequence homology and immunocrossreactivity with another endogenous LPS binding protein, lipopolysaccharide binding protein (LBP). Despite the homology, these proteins have opposite effects on LPS. LBP mediates cell activation by low, otherwise nonstimulatory concentrations, while BPI neutralizes LPS bioactivity. Exogenous LPS binding proteins in the form of monoclonal antibodies have been developed with the goal of generating anti-endotoxin therapeutics to treat gram-negative sepsis and related syndromes. Here we show that LPS-binding and neutralizing properties of BPI compare favorably with two monoclonal antibodies tested, HA-1A and XMMEN-OE5. BPI also competes effectively with LBP for LPS. Thus, BPI may represent an endogenous LPS-regulatory molecule suitable for use as a potent antiendotoxin therapeutic.

引用

页码：134 / 140

页数：7

共 18 条

[1]

References Weiss J., Elsbach P., Olsson I., Et al., Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes, J Biol Chcm, 253, (1978)

[2]

Marra M.N., Wilde C.G., Snable J.L., Et al., Bactericidal/permeability-increasing protein has endotoxin neutralizing activity, J Immunol, 144, (1990)

[3]

Marra M.N., Wilde C.G., Collins M.S., Et al., The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin, J Immunol, 148, (1992)

[4]

Morrison D.C., Ulevitch R.J., Endotoxins and disease mechanisms, Annu Rev Med, 38, (1987)

[5]

Tobias P.S., Mathison J.C., Ulevitch R.J., A family of lipopolysaccharide binding proteins involved in responses to gram-negative sepsis, J Biol Chem, 263, (1988)

[6]

Tobias P.S., Soldau K., Ulevitch R.J., Isolation of a lipopolysaccharidebinding acute phase reactant from rabbit serum, J Exp Med, 164, (1986)

[7]

Schuman R.R., Lcong S.R., Flaggs G.W., Et al., Structure and function of lipopolysaccharide binding protein, Science, 249, (1990)

[8]

Morrison D.C., Ulevitch R.J., The effects of bacterial endotoxins on host mediation systems, Am J Pathol, 93, (1978)

[9]

Ziegler E.J., Fisher C.J., Sprung C.L., Et al., Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: A randomized, double-blind, placebo-controlled trial, N Engl J Med, 324, pp. 429-436, (1991)

[10]

Grccnman R.L., Schcin R.M.N., Martin M.A., Et al., A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis, JAMA, 266, (1991)

← 1 2 →